An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability
Nature Microbiology2016Vol. 2(2), pp. 16199–16199
Citations Over TimeTop 10% of 2016 papers
Marit J. van Gils, Tom L.G.M. van den Kerkhof, Gabriel Ozorowski, Christopher A. Cottrell, Devin Sok, Matthias Pauthner, Jesper Pallesen, Natalia de Val, Anila Yasmeen, Steven W. de Taeye, Anna Schorcht, Stephanie B. H. Gumbs, Inez Johanna, Karen L. Saye-Francisco, Chi-Hui Liang, Elise Landais, Xiaoyan Nie, Laura K. Pritchard, Max Crispin, Garnett Kelsoe, Ian A. Wilson, Hanneke Schuitemaker, Per Johan Klasse, John P. Moore, Dennis R. Burton, Andrew B. Ward, Rogier W. Sanders
Related Papers
- → Capture of an early fusion-active conformation of HIV-1 gp41(1998)497 cited
- → Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion(2006)135 cited
- → Synergistic Inhibition of HIV-1 Envelope-Mediated Membrane Fusion by Inhibitors Targeting the N and C-Terminal Heptad Repeats of gp41(2006)24 cited
- → Evolution of HIV-1 Resistance to a Cholesterol-Linked D-Peptide Fusion Inhibitor(2013)
- Synthesis of an Artificial gp41-C34 Trimer as an HIV-1 Fusion Inhibitor(2013)